US Patent

US10933020 — Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Method of Use · Assigned to Karuna Therapeutics Inc · Expires 2039-09-27 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an oral pharmaceutical composition containing xanomeline and trospium beads for treating disorders improved by muscarinic receptor activation.

USPTO Abstract

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3513 —
U-3513 —
U-3513 —

Patent Metadata

Patent number
US10933020
Jurisdiction
US
Classification
Method of Use
Expires
2039-09-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Karuna Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.